From: Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial
 | Week 24 LOCF | Week 24 PPS | ||||||
---|---|---|---|---|---|---|---|---|
Tianzhi (n = 232) | Donepezil (n = 233) | Placebo (n = 55) | p | Tianzhi (n = 195) | Donepezil (n = 202) | Placebo (n = 46) | p | |
VADAS-cog, mean (SD) | − 6.12 (6.91) | − 6.72 (7.95) | − 3.47 (8.26) | 0.004 | − 6.66 (6.96) | − 7.40 (8.21) | − 3.70 (8.60) | 0.001 |
CIBIC-plus | ||||||||
 Improvement, N (%) | 171 (73.71) | 186 (79.82) | 32 (58.19) | 0.004 | 155 (79.48) | 170 (84.13) | 27 (58.7) | < 0.001 |
 Stable, N (%) | 51 (21.98) | 45 (19.31) | 11 (20.00) | 31 (15.90) | 30 (14.85) | 8 (17.39) | ||
 Deterioration, N (%) | 10 (4.31) | 2 (0.86) | 12 (21.82) | 9 (4.61) | 2 (0.99) | 11 (23.91) | ||
 NPI, mean (SD) | − 3.03 (4.84) | − 2.21 (5.45) | − 0.36 (5.70) | 0.019 | − 2.96 (4.78) | − 2.27 (5.45) | − 0.27 (5.52) | 0.016 |
 MMSE, mean (SD) | 2.19 (2.52) | 2.61 (2.60) | 1.35 (2.67) | 0.025 | 2.19 (2.53) | 2.62 (2.61) | 1.32 (2.69) | 0.023 |
 TMT-A, mean (SD) | − 12.86 (30.80) | − 20.60 (34.97) | − 11.92 (37.38) | 0.009 | − 12.97 (30.85) | − 20.76 (35.11) | − 12.94 (37.86) | 0.015 |
 TMT-B, mean (SD) | − 28.91 (63.96) | − 33.96 (70.53) | − 34.26 (63.08) | 0.439 | − 29.18 (64.02) | − 33.92 (69.13) | − 35.04 (63.59) | 0.523 |
 ADL, mean (SD) | − 1.84 (5.42) | − 1.84 (6.03) | − 0.96 (6.32) | 0.859 | − 1.87 (5.41) | − 1.88 (6.04) | − 1.00 (6.33) | 0.856 |
 CDT, mean (SD) | 0.46 (1.10) | 0.58 (1.15) | 0.40 (1.18) | 0.411 | 0.46 (1.11) | 0.59 (1.15) | 0.47 (1.14) | 0.521 |